Clinical Trials
44 trialsTocilizumab for the Prevention of Graft Versus Host Disease After Cord Blood Transplantation
Memorial Sloan Kettering Cancer Center
TCR1188-ABC Cells in KRAS-mutated Cancers
University of Pennsylvania
SOC Chemotherapy +/- Tocilizumab for Triple Negative and ER-low Breast Cancers
Indiana University
ACTEMRA® for the Treatment of Pediatric Adamantinomatous Craniopharyngioma
Nationwide Children's Hospital
Outpatient Administration of Teclistamab or Talquetamab for Multiple Myeloma
SCRI Development Innovations, LLC
A Phase II Study of the Interleukin-6 Receptor Inhibitor Tocilizumab in Combination With Ipilimumab and Nivolumab in Patients With Unresectable Stage III or Stage IV Melanoma
NYU Langone Health
Tocilizumab, Ipilimumab, and Nivolumab for the Treatment of Advanced Melanoma, Non-Small Cell Lung Cancer, or Urothelial Carcinoma
M.D. Anderson Cancer Center
Tocilizumab in Children With ACP
University of Colorado, Denver
Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma
Emory University
Study of Rituximab or Tocilizumab for Patients With Steroid-Dependent Immune-Related Adverse Events (irAEs)
Columbia University
In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors
University of Southern California
Tocilizumab and Atezolizumab in Adults With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Refractory to 1st Line Immune Checkpoint Inhibitor-Based Therapy
Abramson Cancer Center at Penn Medicine
Phase 2 Study of Glofitamab Monotherapy & With Polatuzumab Vedotin, Pirtobrutinib, or Atezolizumab in Richter's Transformation
Dana-Farber Cancer Institute
Tocilizumab for the Prevention of Graft Failure and GVHD in Haplo-Cord Transplantation
Weill Medical College of Cornell University
Plan Development for Giving Teclistamab in the Outpatient Setting
University Health Network, Toronto
Modified Immune Cells (CD19/CD20 CAR-T Cells) in Treating Patients With Recurrent or Refractory B-Cell Lymphoma or Chronic Lymphocytic Leukemia
Jonsson Comprehensive Cancer Center
Tocilizumab for Prevention of Respiratory Failure in Patients With Severe COVID-19 Infection
Memorial Sloan Kettering Cancer Center
RIOT2
Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute)
Neoadjuvant Atezolizumab-Based Combination Therapy in Men With Localized Prostate Cancer Prior to Radical Prostatectomy
University of California, San Francisco
Preoperative Immunotherapy in Patients With Squamous Cell Carcinoma of the Head and Neck
University of California, San Francisco
Pilot CAR-T Cells Therapy for Children/Young Adults With CD19+ R/R Leukemia/Lymphoma
Belarusian Research Center for Pediatric Oncology, Hematology and Immunology
tMG-E
Tang-Du Hospital
Alemtuzumab or Tocilizumab in Combination With Etoposide and Dexamethasone for the Treatment of Adult Patients With Hemophagocytic Lymphohistiocytosis
M.D. Anderson Cancer Center
GOlDiLOX
Australasian Leukaemia and Lymphoma Group
PACTO
Herlev Hospital
Safety and ASCT-related Symptom Burden Optimization of Tocilizumab in ASCT Following HD Melphalan Conditioning for Multiple Myeloma Patients
The First Affiliated Hospital of Soochow University
Tocilam
Nantes University Hospital
PROACTIVE: Preventing Acute/Chronic GVHD With TocIlizumab Combined With GVHD Prophylaxis Post allogEneic Transplant
Medical College of Wisconsin
CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
Bispecific CD19/CD22 CAR-T for Treatment of Children and Young Adults With r/r B-ALL
Federal Research Institute of Pediatric Hematology, Oncology and Immunology
A Single-arm Trial of Prophylactic Tocilizumab for Acute GVHD Prevention After Haploidentical HSCT.
First Affiliated Hospital of Zhejiang University
Correlation Between Myocardial Injury and Intestinal Flora Changes Associated With Oncology Drug Therapy and the Preventive of Probiotics
Peking University Third Hospital
Evaluating Tocilizumab for Sever COVID-19 Infection in Breast Cancer vs. Non Cancer Pateints
Beni-Suef University
TRIPPLE-R
Herlev Hospital
Nivolumab and Tocilizumab for Relapsed Hematological Malignancy Post-allogeneic Transplant
Medical College of Wisconsin
Trastuzumab and Pertuzumab in Combination With Tocilizumab in Subjects With Metastatic HER2 Positive Breast Cancer Resistant to Trastuzumab
University of Michigan Rogel Cancer Center
Study of the Tocilizumab Optimization Timing for CART19 Associated Cytokine Release Syndrome
University of Pennsylvania
Tocilizumab for the Treatment of Cytokine Release Syndrome in Patients With COVID-19 (SARS-CoV-2 Infection)
Emory University
COLAR
Herlev Hospital
Allogeneic or Haploidentical Stem Cell Transplant Followed By High-Dose Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
Washington University School of Medicine
Study of Tocilizumab in Patients With Hepatocellular Carcinoma (HCC) Undergoing Transarterial Chemoembolization (TACE)
University of Michigan Rogel Cancer Center
Allogeneic Stem Cell Transplantation for Patients With Multiple Myeloma
Washington University School of Medicine
PITCH
Leiden University Medical Center
Feasibility Study of Vessel Analysis for Noninvasive Diagnosis of Malignancy in Breast Tumors
University of North Carolina, Chapel Hill